Company

Taysha Gene Therapies, Inc.

Dallas-based Taysha Gene Therapies develops gene therapies for central nervous system diseases, including Rett syndrome.

About

Founded in 2020 and headquartered in Dallas, US, Taysha Gene Therapies, Inc. develops gene therapies for monogenic diseases of the central nervous system. Its lead product, TSHA-102, targets Rett syndrome, and its customers include patients, healthcare providers and rare disease organizations. The company reported 2024 revenue of USD 8.33 mn and EBITDA of USD -90.21 mn, and it raised USD 40.00 mn in venture debt in September 2020.

3Funding rounds

19Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in